Research articleObstructive and restrictive pulmonary dysfunctions in Parkinson's disease
References (33)
Pleuropulmonary changes during long-term bromocriptine treatment for Parkinson's disease
Lancet
(1981)- et al.
Pleuropulmonary shadows on bromocriptine
Lancet
(1981) - et al.
Bromocriptine-induced collagenosis-like symptomatology in Parkinson's disease
Lancet
(1982) - et al.
Pleuropulmonary involvement during bromocriptine treatment
Chest
(1988) - et al.
Orthostatic hypotension in Parkinson's disease
Lancet
(1972) - et al.
Parkinsonism: onset, progression and mortality
Neurology
(1967) - et al.
Involvement of upper-airway muscles in extrapyramidal disorders
N. Engl. J. Med.
(1984) - et al.
Pulmonary function in Parkinson's disease
J. Neurol. Neurosurg. Psychiat.
(1989) Epidemiology standardization project. III. Recommended standardized procedures for pulmonary function testing
Am. Rev. Respir. Dis.
(1978)- et al.
Site of airway obstruction in asthma as determined by measuring maximal expiratory flow breathing air and helium-oxygen mixture
J. Clin. Invest.
(1972)
The maximal espiratory flow-volume curve. Normal standards, variability and effects of age
Am. Rev. Respir. Dis.
(1976)
Normal values and evaluation of forced end-expiratory flow
Am. Res. Respir. Dis.
(1975)
Maximal respiratory pressures: normal values and relationship to age and sex
Am. Rev. Respir. Dis.
(1969)
Pleuropulmonary changes during long-term bromocriptine treatment for Parkinson's disease
Lancet
(1981)
Fibrose pleuropulmonaire et bromocriptine
Bromocriptine-induced pleuropulmonary fibrosis
Thorax
(1986)
Cited by (112)
Obstructive sleep apnea in Parkinson's disease: A prevalent, clinically relevant and treatable feature
2023, Parkinsonism and Related DisordersParkinson disease and sleep
2023, Encyclopedia of Sleep and Circadian Rhythms: Volume 1-6, Second EditionBreathing disorders in neurodegenerative diseases
2022, Handbook of Clinical NeurologyCitation Excerpt :There appears to be no improvement of FEV1 or FEV1/FVC scores after L-Dopa (Polatli et al., 2001; Monteiro et al., 2012). Restrictive airway disease has been observed in most studies, based on significant reductions in FVC and normal or high FEV1/FVC ratios in 30%–85% of IPD patients (Izquierdo-Alonso et al., 1994; Sabaté et al., 1996; Sathyaprabha et al., 2005; Pal et al., 2007), although a few studies report normal FVC (Hovestadt et al., 1989; Seccombe et al., 2011). It may be worse in the “OFF” medication state (reduced FVC in up to 80% of patients) than in the “ON” state (reduced FVC in up to 70% of patients) (Pal et al., 2007).
Natural history of lung function over one year in patients with Parkinson's disease
2021, Respiratory MedicineVentilatory dysfunction in Parkinson's disease: An unknown disturbance but not without consequences
2020, Pratique Neurologique - FMCOscillometry of the respiratory system in Parkinson's disease: physiological changes and diagnostic use
2023, BMC Pulmonary Medicine
Copyright © 1996 Published by Elsevier B.V.